The two firms are collaborating on a system to share genotypic, phenotypic, and treatment outcomes data with physicians on a mobile-device network.
The partners will work to develop and distribute IROA Technologies' kit for chemically labeling metabolites for mass spectrometry analysis.
The company is also developing a next-generation sequencing product that may be applied at the point of need to test for bloodstream infections and later as a liquid biopsy for cancer.
As part of the agreement, the organizations will develop a joint Seattle-Shenzhen Institute.
The tools the partners plan to develop will help researchers optimize genomic analysis workflows and better identify links between genes and disease.
The partners will develop a new product using MBio's multiplex, point-of-care testing system and Roka's experience in food safety testing.
The partners plan to develop a computational platform that automates pipelines and processes for biomarker discovery, drug recovery and repositioning, and more.
The companies will collaborate on a test to evaluate programmed death-ligand 1 protein expression levels in tumor tissue and its microenvironment.
The innovation hub will be fully operational by end of 2016 or in early 2017 and will be headquartered in the Cambridge Biomedical Campus.
The new release offers faster biomedical literature searches and delivers contextually relevant results to life sciences and healthcare professionals.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.